A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs

Heaney, 2004, Molecular targets in pituitary tumours, Nat Rev Cancer, 4, 285, 10.1038/nrc1320

Asa, 2009, The pathogenesis of pituitary tumors, Annu Rev Pathol, 4, 97, 10.1146/annurev.pathol.4.110807.092259

Lamberts, 2009, Future treatment strategies of aggressive pituitary tumors, Pituitary, 12, 261, 10.1007/s11102-008-0154-y

Resmini, 2007, Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient, J Clin Endocrinol Metab, 92, 1592, 10.1210/jc.2006-2084

Plöckinger, 2008, Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas, J Clin Endocrinol Metab, 93, 1203, 10.1210/jc.2007-1986

Taboada, 2007, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, Eur J Endocrinol, 156, 65, 10.1530/eje.1.02313

Taboada, 2008, Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR, Eur J Endocrinol, 158, 295, 10.1530/EJE-07-0562

Weckbecker, 2003, Opportunities in somatostatin research: biological, chemical and therapeutic aspects, Nat Rev Drug Discov, 2, 999, 10.1038/nrd1255

Fusco, 2008, Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas, Eur J Endocrinol, 158, 595, 10.1530/EJE-07-0806

Bronstein, 2006, Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome, Front Horm Res, 35, 129, 10.1159/000094315

Saveanu, 2001, Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas, J Clin Endocrinol Metab, 86, 140

Durán-Prado, 2009, Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors, J Clin Endocrinol Metab, 94, 2634, 10.1210/jc.2008-2564

Saveanu, 2002, Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells, J Clin Endocrinol Metab, 87, 5545, 10.1210/jc.2002-020934

Saveanu, 2006, Somatostatin and dopamine-somatostatin multiple ligands directed toward somatostatin and dopamine receptors in pituitary adenomas, Neuroendocrinology, 83, 258, 10.1159/000095536

Kilpatrick, 1999, 7TM receptors: the splicing on the cake, Trends Pharmacol Sci, 20, 294, 10.1016/S0165-6147(99)01355-3

Jaquet, 1999, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas, J Clin Endocrinol Metab, 84, 3268

Grant, 2008, Cell Growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization, Mol Endocrinol, 22, 2278, 10.1210/me.2007-0334

Wilson, 1984, A decade of pituitary microsurgery. The Herbert Olivecrona lecture, J Neurosurg, 61, 814, 10.3171/jns.1984.61.5.0814

Jaquet, 2000, Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes, J Clin Endocrinol Metab, 85, 781